A Short Review on Recent Advances in Coagulation Sensors for COVID-19 Disease Management

The COVID-19 disease caused by severe acute respiratory syndrome by the coronavirus-2 (SARS-CoV-2) has affected multiple world regions. COVID-19-induced coagulopathy (CIC) is characterized by a significant increase in D-dimer and fibrin split products and increases in activated partial thromboplastin and prothrombin time seen upon presentation. Biosensors are analytical tools that can provide fast, accurate, and reliable platforms for detecting viruses. This present review emphasizes an overview of the latest progress in biosensor-based diagnosis biomarkers of CIC.